Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab | Zendy

Marc E. Rothenberg | Zendy; Amy D. Klion | Zendy; Florence Roufosse | Zendy; JeanEmmanuel Kahn | Zendy; Peter F. Weller | Zendy; HansUwe Simon | Zendy; Lawrence B. Schwartz | Zendy; Lanny J. Rosenwasser | Zendy; Johannes Ring | Zendy; Elaine F. Griffin | Zendy; Ann Haig | Zendy; Paul Frewer | Zendy; Jacqueline Parkin | Zendy; Gerald J. Gleich | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

Author(s) -

Marc E. Rothenberg,

Amy D. Klion,

Florence Roufosse,

JeanEmmanuel Kahn,

Peter F. Weller,

HansUwe Simon,

Lawrence B. Schwartz,

Lanny J. Rosenwasser,

Johannes Ring,

Elaine F. Griffin,

Ann Haig,

Paul Frewer,

Jacqueline Parkin,

Gerald J. Gleich

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa070812

Subject(s) - mepolizumab , hypereosinophilic syndrome , medicine , eosinophilia , immunology , eosinophil , dermatology , asthma

The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research